By Sean Moloughney, Editor01.26.23
After a review of scientific evidence and three citizen petitions, FDA said “considerable safety concerns” about cannabidiol warrant a new regulatory pathway for CBD, which it wants to develop with Congress.
FDA denied petitions from the Consumer Healthcare Products Association (CHPA), the Council for Responsible Nutrition (CRN), and the Natural Products Association (NPA) to issue a regulation that would allow companies to legally market dietary supplements containing CBD derived from hemp.
Woodcock chairs the FDA’s working group that examined CBD studies in light of an expanding market amid growing consumer demand that follo
FDA denied petitions from the Consumer Healthcare Products Association (CHPA), the Council for Responsible Nutrition (CRN), and the Natural Products Association (NPA) to issue a regulation that would allow companies to legally market dietary supplements containing CBD derived from hemp.
Safety First
In a statement, FDA Principal Deputy Commissioner Janet Woodcock, MD, said the use of CBD raises “various safety concerns, especially with long-term use.”Woodcock chairs the FDA’s working group that examined CBD studies in light of an expanding market amid growing consumer demand that follo
Continue reading this story and get 24/7 access to Nutraceuticals World for FREE
FREE SUBSCRIPTION
